Fig. 1: Antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N). | Communications Medicine

Fig. 1: Antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N).

From: Compartmentalised mucosal and blood immunity to SARS-CoV-2 is associated with high seroprevalence before the Delta wave in Africa

Fig. 1

Participants are grouped by reactivity to both antigens (serostatus = S+N+, S+N−, S−N+ and S−N−). a The proportion of participants within each serostatus group (upper panel) and quantitative spike and binding nucleocapsid antibody (lower panel) in pre-pandemic sera (n = 825). b The proportion of participants within each serostatus group (upper panel) and quantitative spike and binding nucleocapsid antibody (lower panel) following the first two SARS-CoV-2 waves (n = 349). Boxplots depict means with 95% confidence intervals. BAU/mL = binding antibody units/mL. Wilcoxon rank sum test was used to compare responses between S antibody responses in S+N+ and S+N− groups, as well as N antibody responses in S+N+ and S−N+ groups. c Seroprevalence estimates for each age category based on spike reactivity, adjusted for household clustering. The vertical error bars indicate the 95% confidence intervals (CIs) of the estimates for the different age categories: <5 years, 5–17 years, 18–49 years and 50+ years.

Back to article page